Marginal zone lymphomas: factors that affect the final outcome.
about
Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic reviewMolecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type.Tissue proteomics of splenic marginal zone lymphoma.Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for ISurvival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database.Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites.Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma.Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients.Incidence of gastric involvement in patients with nongastrointestinal extranodal marginal zone lymphoma.Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation.Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).
P2860
Q26996650-01530463-93D3-410C-8BDD-87D09FD7F01DQ37944372-65E0C16B-82A9-4629-9838-991ED133C729Q38413335-6AB365A7-42C5-47E6-A50D-22AC727973ACQ40281190-0BCB23F9-53F5-46F9-9772-9F1875DCCCA8Q42377778-8EA6ED42-ED22-4D6E-90F1-17A45AA0A121Q44223923-C0922986-4D7E-4210-8210-C0A3D1BAD2ECQ44854299-CB446EA8-8D10-40F6-835A-D01AC08C15AFQ45756830-B1CE422C-AB2A-4265-88B7-903D7C09C316Q47449201-FAA2D599-B7F1-42D2-9B2F-58D0567EF201Q51457141-34BAB0CF-F3FE-4DD2-86AA-1FE206FB577AQ51626523-ED2B989C-80D4-44B9-A08A-900484DC0080Q53208977-2A81C549-9CF1-41C6-80B9-0D8C1E052376Q53244764-EDCB6BB2-B380-470C-8715-3E7CF7A9D81CQ53357340-682D8EF9-4FAA-4433-B270-B684E3F91D42
P2860
Marginal zone lymphomas: factors that affect the final outcome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Marginal zone lymphomas: factors that affect the final outcome.
@en
Marginal zone lymphomas: factors that affect the final outcome.
@nl
type
label
Marginal zone lymphomas: factors that affect the final outcome.
@en
Marginal zone lymphomas: factors that affect the final outcome.
@nl
prefLabel
Marginal zone lymphomas: factors that affect the final outcome.
@en
Marginal zone lymphomas: factors that affect the final outcome.
@nl
P2093
P356
P1433
P1476
Marginal zone lymphomas: factors that affect the final outcome.
@en
P2093
Ali Mazloom
Barbara Pro
Bouthaina S Dabaja
Diana L Urbauer
Fernando F Cabanillas
Graciela Gonzalez
L Jeffrey Medeiros
Luis E Fayad
Peter W McLaughlin
Puneeth Iyengar
P304
P356
10.1002/CNCR.25325
P407
P50
P577
2010-09-01T00:00:00Z